Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyJ. E. Wraith, J Zeman, Nathalie Guffon et al.|European Journal of Pediatrics|2007Cited by 522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Stuart J. Swiedler, Ida Vanessa Döederlein Schwartz et al.|The Journal of Pediatrics|2006Cited by 364
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Stephen Waldek et al.|Journal of Medical Genetics|2015Cited by 363
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseMaurizio Scarpa, J. E. Wraith, Zsuzsanna Almássy et al.|Orphanet Journal of Rare Diseases|2011Cited by 231
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Celeste Decker, Roberto Giugliani et al.|Molecular Genetics and Metabolism|2008Cited by 216